Back to Search
Start Over
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.
- Source :
-
Trends in cancer [Trends Cancer] 2020 Feb; Vol. 6 (2), pp. 130-146. Date of Electronic Publication: 2020 Jan 21. - Publication Year :
- 2020
-
Abstract
- The approval of ado-trastuzumab emtansine (T-DM1) for clinical use represented a turning point both in HER2-positive breast cancer treatment and antibody-drug conjugate (ADC) technology. T-DM1 has proved its value and effectiveness in advanced metastatic disease as well as in the adjuvant setting. However, its therapeutic potential extends beyond the treatment of breast cancer. Around 100 clinical trials have evaluated or are studying different aspects of T-DM1, such as its role in other HER2 malignancies, rational combinations with immunotherapy, or its function in brain metastasis. Conceptually, many lessons can be learned from this ADC. Understanding its mechanisms of action and the molecular basis underlying resistance to T-DM1 may be relevant to comprehend resistances raised to other ADCs and identify pitfalls that may be overcome.<br /> (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Subjects :
- Ado-Trastuzumab Emtansine therapeutic use
Antineoplastic Agents, Immunological therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Breast pathology
Breast surgery
Breast Neoplasms immunology
Breast Neoplasms mortality
Breast Neoplasms pathology
Chemotherapy, Adjuvant methods
Clinical Trials as Topic
Drug Resistance, Neoplasm drug effects
Female
Humans
Immune Checkpoint Inhibitors pharmacology
Immune Checkpoint Inhibitors therapeutic use
Immunotoxins therapeutic use
Mastectomy
Neoadjuvant Therapy methods
Progression-Free Survival
Receptor, ErbB-2 antagonists & inhibitors
Receptor, ErbB-2 metabolism
Ado-Trastuzumab Emtansine pharmacology
Antineoplastic Agents, Immunological pharmacology
Antineoplastic Combined Chemotherapy Protocols pharmacology
Breast Neoplasms therapy
Immunotoxins pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 2405-8025
- Volume :
- 6
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Trends in cancer
- Publication Type :
- Academic Journal
- Accession number :
- 32061303
- Full Text :
- https://doi.org/10.1016/j.trecan.2019.12.010